TRR 338:  LETSIMMUN - Lymphocyte Engineering for Therapeutic Synthetic Immunity

• Subject Area: Medicine ; Biology
• Term: since 2021
• Website: Homepage
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 452881907

No abstract available

• DFG Programme: CRC/Transregios

Current projects

• A01 - Orthotopic T cell receptor replacement by advanced non viral cell engineering (Project Head Busch, Dirk )
• A02 - One CAR – multiple antigens: Universal CAR-T cells that are chemically programmed to recognize tumors (Project Heads Hudecek, Michael ;  Weber, Wolfgang A. )
• A04 - Extending and controlling lymphocyte functionalities by engineered cytokines (Project Head Feige, Matthias )
• A05 - Super-resolution microscopy to visualize CAR-T cell receptome and function (Project Heads Nerreter, Thomas ;  Sauer, Markus )
• A07 - Developing polyclonal TCR-T cell therapies using CRISPR base and prime editing (Project Heads D' Ippolito, Ph.D., Elvira ;  Petri, Karl )
• A08 - AI-Powered Chimeric Receptors to Overcome Therapeutic Resistance in Myeloma (Project Head Schmidts, Andrea )
• B01 - Disease specific engineering of CAR T cells utilizing chemokine receptors (Project Heads Kobold, Sebastian ;  Subklewe, Marion )
• B02 - Engineering CAR-T cells to optimize the treatment of cerebral malignancies (Project Heads von Baumgarten, Louisa ;  Buchholz, Veit ;  Künkele-Langer, Annette )
• B03 - Engineering tissue-resident lymphocytes for the modulation of tissue-microenvironments (Project Head Gasteiger, Georg )
• B04 - T cell engineering to overcome immune dysregulation induced by acute leukemia (Project Head Feuchtinger, Tobias )
• B05 - Engineering of CAR-T cells that overcome MYC-dependent immunosuppression in a genetically engineered mouse model of pancreatic cancer (Project Heads Bräunlein, Ph.D., Eva ;  Danhof, Sophia ;  Eilers, Martin )
• B06 - Engineering a sustainable and non-exhausting CD8+ T cell response (Project Head Kastenmüller, Wolfgang )
• B07 - Overcoming barriers for T cell therapy of hepatitis B and hepatocellular carcinoma (Project Head Protzer, Ulrike )
• C01 - Exploitation of negative regulators of TCR signaling for therapeutic lymphocyte engineering (Project Head Ruland, Jürgen )
• C02 - Post-transcriptional control of metabolic programs that improve T cell responses against tumors (Project Heads Heissmeyer, Vigo ;  Milles, Lukas )
• C03 - Targeting T cell-intrinsic negative regulators to enhance the therapeutic potential of adoptive T cell therapy (Project Head Hornung, Veit )
• C04 - Dissection and correction of human regulatory T cell dysfunctions by CRISPR engineering (Project Heads Kotlarz, Daniel ;  Luu, Maik ;  Schumann, Ph.D., Kathrin )
• C05 - Metabolic reprogramming to optimize the cellular fitness and function of engineered T cells (Project Heads Theurich, Sebastian ;  Vaeth, Martin )
• Z - Central Tasks of the Collaborative Research Center (Project Head Busch, Dirk )
• Z02 - Bench-to-Bedside Advanced Therapy Medicinal Product (ATMP) Development Platform (Project Heads Einsele, Hermann ;  Hildebrandt, Martin ;  Lindemann, Anja ;  Marckmann, Georg ;  Priesner, Christoph )
• Z03 - Integrative analysis of single cell genomics and immunoprofiling (Project Heads Canzar, Stefan ;  Klughammer, Ph.D., Johanna ;  Theis, Fabian )

Completed projects

• A03 - Targeting neoantigens in multiple myeloma by TCR-transgenic T cells (Project Head Krackhardt, Angela )
• A06 - Engineering CAR-T cells against neuroblastoma with synthetic notch receptors to increase tumor-specificity and endogenous immune activation (Project Head Künkele-Langer, Annette )

• Applicant Institution: Technische Universität München (TUM)
• Co-Applicant Institution: Julius-Maximilians-Universität Würzburg; Ludwig-Maximilians-Universität München
• Participating Institution: Charité - Universitätsmedizin Berlin
• Participating University: Universitätsklinikum Freiburg der Albert-Ludwigs-Universität Freiburg
• Spokesperson: Professor Dr. Dirk Busch